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Received November 19, 2015; accepted June 21, 2016AbstractBackground: The aim of this study was to verify the accuracy of a formula predicting postoperative intraocular pressure (IOP) after phaco-
emulsification and intraocular lens implantation (PHCE-IOL) in primary angle-closure glaucoma (PACG). In a retrospective chart review of
patients with PACG who underwent PHCE-IOL between 2011 and 2014, we collected preoperative IOP, axial length, anterior chamber depth
(ACD), number of pre-PHCE glaucoma medications, and IOP and glaucoma medications at 1 month and 3 months post-PHCE.
Methods: Post-PHCE IOP values at 1 month and 3 months were compared with those predicted using the formula: postoperative
IOP ¼ 6.354 þ 0.186 pre-PHCE IOP  pre-PHCE ACD. Agreements between measured and predicted IOP values were analyzed using cor-
relation coefficients and BlandeAltman plots.
Results: Of the 62 eyes included, the average pre-PHCE IOP was 19.47 ± 5.84 mm Hg. Post-PHCE IOP values were 14.94 ± 4.03 mm Hg at
1 month and 14.21 ± 3.51 mm Hg at 3 months. Patients using more preoperative medications tended to show greater postoperative declines in
medication usage. Predicted IOP significantly correlated with post-PHCE IOP measured at 1 month (R ¼ 0.314, p ¼ 0.013) and 3 months
(R ¼ 0.325, p ¼ 0.01). BlandeAltman plots of difference against average of measured and estimated IOP revealed two cases falling
outside± 1.96 standard deviation at 1 month, and five cases at 3 months, indicating good consistency between measurement and prediction.
Conclusion: This formula was useful for predicting IOP at 1 month and 3 months after PHCE-IOL in PACG. It aids clinicians in preoperative
assessment of whether PHCE-IOL alone is likely to achieve acceptable postoperative IOP control.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Primary angle-closure glaucoma (PACG) is estimated to be
responsible for approximately half of the cases of binocular
glaucoma blindness worldwide.1,2 Accumulating evidence
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).chamber narrowing. Aging is associated with a progressive
increase in the number of lens fibers, with corresponding in-
creases in lens thickness and anterior curvature. This leads to
decreasing depth of the anterior chamber and narrowing of the
chamber angle, especially in eyes with shorter axial length
(AL).3,4 Numerous studies have demonstrated that phaco-
emulsification with intraocular lens implantation (PHCE-IOL)
substantially widens the anterior chamber angle and reduces
intraocular pressure (IOP) in eyes with PACG.5e9 Different
studies have reported average IOP reductions ranging from 6%
to 32%, possibly depending on the preoperative IOP level and
the duration of postoperative follow-up.7,10e17 Even highersevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1
Characteristics of the 62 PACG eyes and preoperative and postoperative data.
Characteristics (n ¼ 62) Mean ± SD
Age (y) 74.1 ± 0.2
Pre-PHCE BCVA (LogMAR) 0.61 ± 0.39
Pre-PHCE vertical C/D ratio 0.76 ± 0.17
Pre-PHCE visual field mean deviation (dB) 12.81 ± 9.03
Central corneal thickness (mm) 554.9 ± 38.6
Pre-PHCE anterior chamber depth (mm)a 2.50 ± 0.31
Pre-PHCE axial length (mm)a 23.07 ± 1.10
Intraocular pressure (IOP)
Pre-PHCE IOP (mmHg)a 19.5 ± 5.8
Post-PHCE IOP at month 1 14.9 ± 4.0
Post-PHCE IOP at month 3 14.2 ± 3.5
Estimated IOP 15.4 ± 2.8
No. of glaucoma medications
Pre-PHCE number of medicationsb 2.0 ± 1.3
Post-PHCE number of medicationsc 0.9 ± 0.9
BCVA ¼ best corrected visual acuity; C/D ratio ¼ cup-to-disc ratio;
IOP ¼ intraocular pressure; PHCE ¼ phacoemulsification; SD ¼ standard
deviation.
a Preoperative measurement within 1 month of surgery.
b Preoperative number of medications within 1 month before surgery.
c Postoperative number of medications at 3 months after surgery.
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acute PACG.18e20
Although cataract extraction is an effective IOP-lowering
treatment, it is sometimes insufficient for long-term IOP
control. In cases of chronic PACG where IOP is not medically
controlled before PHCE-IOL, up to 12% might require inva-
sive glaucoma intervention for IOP control within 2 years after
cataract surgery.12 Other studies have reported the need for
further operations in 3e16% of cases.11,13,14 Siriwardena
et al21 demonstrated greater and more prolonged anterior
chamber flare at 3 months after cataract surgery compared
with trabeculectomy, suggesting that glaucoma filtering sur-
gery conducted a few months after cataract surgery carries a
higher risk of surgical failure. To aid preoperative decision
making, we have demonstrated in a prospective study that
preoperative anterior chamber depth (ACD) and IOP are sig-
nificant predicting factors for IOP at 3 months after PHCE-
IOL in eyes with PACG.10 These findings were confirmed in
a subsequent study with a longer follow-up period, and a
formula was then constructed to predict IOP at 12 months after
cataract surgery in eyes with PACG.11
The present study aimed to test whether the formula pre-
viously derived from 12-month postoperative data was appli-
cable for estimating short-term IOP at 1 month and 3 months
after PHCE -IOL in another group of PACG eyes. This
knowledge would assist with preoperative decision making to
determine which eyes would benefit most from cataract sur-
gery alone in terms of IOP control, thus avoiding complica-
tions of unnecessary combined cataract and glaucoma
surgery.22
2. Methods
We retrospectively reviewed the charts of all PACG patients
who underwent PHCE-IOL performed by one surgeon (C.J.L.)
at Taipei Veterans General Hospital from January 2011 to June
2014. The included surgical procedures all comprised tem-
poral clear-cornea phacoemulsification with in-the-bag im-
plantation of some variety of one-piece AcrySof (Alcon, Fort
Worth, TX, USA) IOL selected based on each patient's needs
and preferences. The study was reviewed by the Institutional
Review Board in Taipei Veterans General Hospital. Informed
consent was not necessary because this was a retrospective
chart review. All patients' information was de-identified prior
to data analysis and was analyzed anonymously.
PACG was diagnosed based on findings of occludable
anterior chamber angle and characteristic glaucomatous optic
neuropathy. An anterior chamber angle was considered
occludable when <90 of the posterior trabecular meshwork
was visible on static gonioscopy in a dark room with the eye in
the primary position. Glaucomatous optic neuropathy was
defined as an optic disc showing vertical cup elongation, focal
neuroretinal rim thinning or notching, or an asymmetric cup-
to-disc ratio of >0.2 between the two eyes, as well as corre-
sponding retinal nerve fiber bundle visual field defects. The
study excluded eyes with angle closure secondary to uveitis,
neovascularization, tumor, posterior segment disease, orsurgery, as well as eyes that had undergone ocular laser sur-
gery or surgery other than laser peripheral iridotomy (LPI).
Also excluded were eyes with corneal diseases that might
influence IOP measurement, patients with concurrent diseases
that might cause visual field defects, and patients with a post-
PHCE-IOL follow-up period of <3 months.
Within 1 month before PHCE-IOL, all patients underwent
ophthalmic examinations, including best-corrected visual
acuity (BCVA), ocular biometry, slit-lamp biomicroscopy,
tonometry, gonioscopy, fundoscopy, and automated perimetry.
AL and ACD were measured using IOLMaster V.5.02 (Carl
Zeiss Meditec, Oberkochen, Germany). For each patient, we
recorded the IOP by noncontact tonometry and number of
glaucoma medications taken before PHCE-IOL, and at
1 month and 3 months after PHCE-IOL. Fixed combination
glaucoma medication e such as Cosopt (Merck Sharp and
Dohme, Whitehouse Station, NJ, USA), Combigan (Allergan
Australia, Irvine, CA, USA), or Azarga (Alcon Canada, Alcon
Pharma GmbH, Puurs, Belgium) e was counted as two
medications.
The estimated numerical value of the postoperative IOP was
calculated using the following formula: IOP after PHCE-
IOL ¼ 6.354 þ (0.186 pre-PHCE IOP  pre-PHCE ACD).11
Spearman correlation analysis was used to compare the esti-
mated postoperative IOP with the measured IOP values ob-
tained at 1 month and 3 months after cataract surgery. The
agreement between the estimated and measured IOP values
was also analyzed by BlandeAltman plot. All analyses were
performed using SPSS version 20.0 (SPSS, Chicago, IL, USA).
3. Results
A total of 62 eyes (54 patients) were included in the data
analysis. Table 1 shows the patients' characteristics. The
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patients underwent uneventful clear cornea PHCE-IOL. No
patients required surgical intervention within 3 months
following cataract surgery.
Of the operated eyes, 63% had received LPI before un-
dergoing cataract surgery. The average pre-PHCE IOP was
19.47 ± 5.84 mm Hg while being treated with an average of
2.0 ± 1.3 glaucoma medications. The post-PHCE IOP was
14.94 ± 4.03 mm Hg at 1 month and 14.21 ± 3.51 mmHg at
3 months. Compared with preoperative levels, postoperative
IOP was decreased by 4.26 mm Hg (a 23% reduction) at
1 month and by 5.26 mm Hg (a 26% reduction) at 3 months.
Preoperatively, 56 eyes (90%) were treated with glaucoma
medication: seven with >3 medications, 16 with three medi-
cations, 15 with two medications, and 18 with one medication.
At 3 months after surgery, 10 eyes (18%) required the same
number of medications for IOP control, 29 eyes (52%)
required one less medication, 12 eyes (21%) required two less
medications, three eyes (5%) required three less medications,
and one eye (1.7%) required four and five less medications
after surgery. There was a trend toward a greater postoperative
reduction of glaucoma medications with increasing number of
preoperative glaucoma medications required (Fig. 1).
Correlation analysis revealed that the estimated post-PHCE
IOP values derived using the previously developed formula
were positively correlated with the measured IOP values at
1 month (R ¼ 0.314, p ¼ 0.013; Fig. 2A) and 3 months
(R ¼ 0.325, p ¼ 0.01; Fig. 2B) after surgery. We found no
significant difference between 1-month IOP and estimated IOP
( p ¼ 0.396). The 3-month IOP significantly differed from the
estimated IOP ( p ¼ 0.024). However, this difference was no
longer significant ( p ¼ 0.081) when we excluded the two
outliers that were distant from other clustered points on the
scattered plot (indicated by arrows in Fig. 2A and 2B). These
points represented data from the same two eyes at 1 month and
3 months after surgery. Both of these cases showed elevatedFig. 1. The ordinate axis shows changes in the number of glaucoma medica-
tions at 3 months after cataract surgery. The abscissa axis shows the numbers
of preoperative glaucoma medications.IOP lasting for several weeks following an episode of acute
angle closure attack; after which, the patients were referred to
us for further treatment. None of the other cases enrolled in
this study had a history of acute angle closure attack.
The BlandeAltman plots also revealed good agreement
between the estimated and the measured IOP values at
1 month and 3 months postoperatively (Figs. 3 and 4). The
measurements for two eyes fell outside of± 1.96 standard
deviation (SD) from the mean difference between the esti-
mated and measured IOP at 1 month, and the measurements
for five eyes were outside of this range at 3 months. Each of
these five eyes had a pre-PHCE IOP >27 mm Hg, and four of
these eyes were treated with 3 glaucoma medications before
PHCE-IOL. Of these five cases, only one eye had a measured
IOP value that was higher than the estimated value at 3 months
after surgery, while the other four eyes had measured IOP
values lower than the estimated values.
4. Discussion
The present study investigated eyes with PACG that were
treated with PHCE-IOL, and found mean IOP reductions of
23% at 1 month postoperatively and of 26% at 3 months
postoperatively. Direct comparisons of our study with previous
reports are difficult because of differing study designs, but our
results were in agreement with previous reports that showed a
reduction of 8e31% at 3 months after cataract surgery.7,10e14
Moreover, none of the included 62 eyes required additional
glaucoma medication or further glaucoma intervention to
control IOP during the first 3 months postoperatively. In fact,
we found that eyes that were preoperatively treated with more
glaucoma medications tended to obtain a greater reduction in
the number of medications 3 months postoperatively. To the
best of our knowledge, this has not previously been reported,
and its clinical implication warrants further investigation.
More importantly, 92% of the eyes in our study achieved a
postoperative measured IOP that was in agreement, based on
the BlandeAltman plot, with the estimated IOP calculated
using our previously constructed formula (5 patients fell
outside the ± 1.96 SD of the BlandeAltman plot, representing
“not in agreement”).11 The differences between the estimated
and measured IOP values were within ± 3.0 mm Hg in 32 eyes
(52%) at 1 month postoperatively and in 42 eyes (68%) at
3 months postoperatively. The utilized formula had been
constructed based on 12-month postoperative IOP data from
another group of chronic PACG eyes, but it still provided
reasonable estimations of postoperative IOP at 1 month and
3 months after PHCE and IOL implantation in our present
study group. In clinical practice, estimation of IOP within
3 months of cataract surgery may be more important than
long-term IOP estimation. After cataract surgery alone, post-
operative IOP may become more difficult to control because of
ocular inflammation and steroid use. Patients who are preop-
eratively using three or more glaucoma medications have only
limited choices of additional glaucoma drugs to reduce pres-
sure elevation, and additional glaucoma surgery performed
Fig. 2. The scatter plots illustrate the relationships between the estimated IOP and the measured IOP values obtained at 1 month postoperatively (A) and 3 months
postoperatively (B). Circles falling on the oblique line represented cases for which the measured IOP was equal to the estimated IOP. The black arrows indicate the
two outliers in each plot. IOP ¼ intraocular pressure.
Fig. 3. This BlandeAltman plot shows the IOP average against the difference
between the estimated IOP and measured IOP at 1 month after surgery. The
three horizontal lines represent þ1.96 SD (8.37 mm Hg), the mean
(0.44 mmHg), and 1.96 SD (7.50 mmHg) of the difference between the
two values. The different shapes represent different numbers of preoperative
medications: B ¼ no medication; , ¼ 1 medication;  ¼ 2 medications;
△ ¼ 3 medications; þ ¼ 4 medications; 0 ¼ 5 medications).
IOP ¼ intraocular pressure; SD ¼ standard deviation.
Fig. 4. This BlandeAltman plot shows the IOP average against the difference
between the estimated IOP and measured IOP at 3 months after surgery. The
three horizontal lines represent þ1.96 SD (8.95 mm Hg), the mean (1.17 mm
Hg), and 1.96 SD (6.62 mm Hg) of the difference between the two values.
The different shapes represent different numbers of preoperative medications:
B ¼ no medication; , ¼ 1 medication;  ¼ 2 medications; △ ¼ 3 medi-
cations; þ ¼ 4 medications; 0 ¼ 5 medications). IOP ¼ intraocular pressure;
SD ¼ standard deviation.
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due to inflammation.10
Two eyes in our present study were found to be outliers in
both the correlation analysis and the BlandeAltman plots at
Postoperative Months 1 and 3. The pre-PHCE IOPs of these
eyes were 34 mm Hg and 38 mm Hg, respectively, while on
three glaucoma medications, including oral acetazolamide.
Pre-PHCE gonioscopy revealed 360 peripheral anteriorsynechia with slit opening inferiorly on indentation. The IOP
values measured at 3 months after surgery (11 mm Hg and
12 mm Hg, respectively) were lower than the estimated IOP
values (23.11 mm Hg and 25.01 mm Hg, respectively) for
these two cases. These were the only two eyes in this study
that had been afflicted with an acute episode of angle closure
within 1 month of cataract surgery. Medical intervention
following the acute attack reduced the IOP, but medication did
676 Y.-F. Chang et al. / Journal of the Chinese Medical Association 79 (2016) 672e677not lower the IOP to <30 mmHg before PHCE-IOL. In such
cases, a large anterior-placed lens,8,15 potentially compro-
mised trabecular outflow,23,24 inflammation, and ocular
congestion with uveal effusion and anterior rotation of the
ciliary body may all contribute to making it difficult to control
the IOP with glaucoma medication.3,25 However, the impact of
inflammation and ocular congestion on aqueous drainage
outflow may be reversible after lens removal and inflammation
control, which may at least partly explain why the measured
postoperative IOP was lower than the estimated value. In the
study from which the IOP-estimation formula was devel-
oped,11 all patients had PACG with IOP that was controlled
before cataract extraction. A few cases had a history of acute
attack, but these acute attacks had occurred years earlier.
Accumulating evidence, including our present findings,
demonstrates that PHCE-IOL can lower IOP and reduce the
need for glaucoma medication. Studies using ultrasound bio-
microscopy, Scheimpflug videophotography, rotating camera
scanner, and anterior segment optical coherence tomography
reveal increases of the width and depth of the anterior chamber
angle in PACG after cataract surgery, to the extent that they
become similar to normal eyes.18,26e29 By comparing preop-
erative and postoperative gonioscopy findings, Lai et al16
demonstrated a decrease in the extent of peripheral anterior
synechial closure after PHCE in eyes with PACG and coex-
isting cataract. This could be caused by resolution of synechia
with weak adherence to the trabeculum through the positive
flushing pressure and viscoelastic agent injection into the
anterior chamber during PHCE, as well as to the removal of a
bulky lens. Moreover, the increased trabecular outflow facility
induced by the PHCE ultrasound may also contribute to IOP
reduction after surgery. Previous studies have shown improved
aqueous outflow facility after PHCE,30 which may be related
to interleukin-1a production from the trabecular meshwork
cells in response to PHCE ultrasound.31
In conclusion, the present study demonstrated that our
previously constructed IOP estimation formula, which utilizes
preoperative IOP and ACD, is useful for estimating IOP at
1 month and 3 months after surgery. The proposed prediction
formula provides another piece of information in preoperative
patient consultation about whether PHCE-IOL alone is likely
to achieve the target IOP each individual eye requires, so as to
avoid life-long potential complications of combined glaucoma
filtering surgery.
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